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Abstract
Objective—To assess the cost-effectiveness of a pilot newborn screening (NBS) and treatment 
program for sickle cell anemia (SCA) in Luanda, Angola.
Study design—In July 2011, a pilot NBS and treatment program was implemented in Luanda, 
Angola. Infants identified with SCA were enrolled in a specialized SCA clinic in which they 
received preventive care and sickle cell education. In this analysis, the World Health Organization 
(WHO) and generalized cost-effectiveness analysis methods were used to estimate gross 
intervention costs of the NBS and treatment program. To determine healthy life-years (HLYs) 
gained by screening and treatment, we assumed NBS reduced mortality to that of the Angolan 
population during the first 5 years based upon WHO and Global Burden of Diseases Study 2010 
estimates, but provided no significant survival benefit for children who survive through age 5 
years. A secondary sensitivity analysis with more conservative estimates of mortality benefits also 
was performed. The costs of downstream medical costs, including acute care, were not included.
Results—Based upon the costs of screening 36 453 infants and treating the 236 infants with SCA 
followed after NBS in the pilot project, NBS and treatment program is projected to result in the 
gain of 452-1105 HLYs, depending upon the discounting rate and survival assumptions used. The 
corresponding estimated cost per HLY gained is $1380-$3565, less than the gross domestic 
product per capita in Angola.
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Conclusions—These data demonstrate that NBS and treatment for SCA appear to be highly 
cost-effective across all scenarios for Angola by the WHO criteria.
Sickle cell disease is a significant global public health problem. In 2010, an estimated 312 
000 infants throughout the world were born with homozygous sickle cell disease, a 
condition known as sickle cell anemia (SCA), the majority in sub-Saharan Africa.1 Mortality 
in SCA historically has been extremely high, with death often occurring before a diagnosis 
is made.2-4 In high-income countries, early diagnosis by newborn screening (NBS) and 
access to comprehensive care have resulted in survival to adulthood of over 95%.5,6 
Implementation of NBS and early preventive care also has led to improved SCA survival in 
resource-limited settings, as demonstrated in Jamaica.7,8 In the US, universal NBS has been 
demonstrated to be cost-effective.9,10 A similar study in the United Kingdom was 
inconclusive, but universal screening was adopted nevertheless.10 Additional data regarding 
the cost-effectiveness of NBS, particularly in resource-limited settings, are limited. In 
contrast, routine NBS and access to treatment are not widely available in sub-Saharan Africa 
despite sporadic reports of pilot screening and treatment programs.11-16 The World Health 
Organization (WHO) has challenged African nations to address urgently the growing burden 
of SCA,17,18 but SCA remains a low priority compared with other health problems.19
Our study intended to demonstrate that NBS for SCA accompanied by preventive care can 
be cost-effective in a high prevalence, resource-constrained setting in sub-Saharan Africa. 
This study began as part of a 3-way collaboration among Chevron, Baylor College of 
Medicine, and the Ministry of Health in the Republic of Angola. The pilot NBS and 
treatment program, performed in Luanda, Angola, demonstrated a 1.5% prevalence of SCA 
in newborns.11 The pilot program demonstrated the feasibility of performing both NBS and 
early clinical care in this limited-resource setting. The current analysis builds upon the pilot 
study by analyzing costs and projected mortality and morbidity changes to address the 
question of NBS cost-effectiveness. In so doing, we hope to provide information on the 
potential costs and health impact of implementation of NBS for SCA in an African setting.
Methods
In this report, we use data from the pilot program to perform a cost-effectiveness analysis 
(CEA) of a realistic model for NBS and treatment in Angola.
We used the modified WHO-choosing Interventions that are cost-effective (CHOICE) and 
generalized CEA methods to estimate intervention costs in order to maximize 
generalizability.20 Intervention costs were calculated for 2 components: (1) the pilot NBS 
program; and (2) the provision of care through age 5 years to those enrolled for care during 
the 2-year pilot phase. Costs of tradeable goods were converted to international dollars (I$) 
using the market exchange rate and untradeable goods and services using the purchasing 
power parity exchange rate.21,22
Screening costs included supplies for sample collection, maternity nurse labor for specimen 
collection, transport of samples to the central laboratory, and laboratory costs to include 
personnel to perform isoelectric focusing on all samples. Care costs included personnel 
(doctors, nurses, and clinic coordinator) and treatments, as well as clinic overhead (physical 
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space, telecommunications, and computer needs). Treatment costs were calculated as the 
expected costs of providing ongoing sickle cell education and routine clinical care, including 
measurement of hemoglobin and provision of mosquito nets, folic acid, and oral 
prophylactic penicillin, every 3 months through 5 years of age. Although the pilot program 
provided pneumococcal conjugate vaccine, this is now publicly available for all Angolan 
children, and these costs were not included. The cost of a single dose of 23-valent 
pneumococcal polysaccharide vaccine ($35) was included, as this is not a standard vaccine 
for children in Angola. Supplies were priced according to actual costs incurred using in-
country vendors. Except for a few supplies carried over at the onset of the program, all 
equipment and supplies were sourced locally.
Given the novelty of and expertise to implement NBS in Africa, the pilot program required 
foreign personnel to assist with program development. Cost of foreign personnel was not 
included as they are assumed to not be an integral part of its continuation, but as a subset of 
roles were considered essential, we did include the estimated cost of employing Angolans 
with similar qualifications. The pilot program used an internet-based database with servers 
located in the US, primarily for research and reporting progress to the project sponsor. US-
based technology costs were not included, but essential information technology 
infrastructure and personnel in Luanda were included. Per WHO-CHOICE methodology and 
because of the lack of data on the costs and utilization of the healthcare system by patients 
with SCA, estimates of downstream medical costs were not included. Advanced laboratory 
tests, such as a complete blood count or reticulocyte counts, are not routinely measured and 
were not included.
Projection of Health Gain
To determine the health effect of NBS and treatment in Luanda, we quantified the 
simultaneous effects of decreased mortality and increased morbidity (inherent in longer 
survival) among patients with SCA. Disability-adjusted life-years (DALYs) and quality-
adjusted life years (QALYs) are 2 metrics that quantify mortality and morbidity 
simultaneously, but neither is ideal for CEA. Death results in no further accumulation of 
QALYs and/or a loss of DALYs equivalent to life expectancy at time of death. The latter 
generally is done with respect to a global standard life table. DALYs calculate morbidity 
using disability weights (DWs) ranging from 0 (perfect health) to 1 (equivalent to death). 
QALYs are the inverse, relying on a range of health-related quality of life (HRQoL) scores 
from 1 (perfect health) to 0 (equivalent to death) to quantify morbidity. A year lived in 
perfect health will, thus, result in 1 QALY gained and 0 DALYs lost.
The WHO-CHOICE manual recommends researchers either calculate “QALYs gained” or 
“DALYs averted,” but specifies that for CEA purposes, DALY-based methods should not 
use a reference life table because population-level interventions can affect overall life 
expectancy estimates. The manual further states, “For CEA, full health is valued at 1, with 0 
representing the worse possible state of health, in this case death.”20 The Global Burden of 
Diseases, Injuries, and Risk Factors (GBD) Study 2010 has provided an analytic method for 
calculating DALYs, including DWs for SCA-related health states.23 Unfortunately, there is 
no internationally comparable set of HRQoL scores. We, therefore, calculated health 
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improvements in Luanda using a metric called healthy life-years (HLYs) gained, did not use 
a reference life table, and approximated HRQoL scores as 1-DW from the GBD 2010 Study. 
HLYs gained is intended to distinguish this metric from both QALYs gained and DALYs 
averted, but still convey that we yet value full health at 1 rather than 0.
Estimates of Decreased Mortality
There are no definitive data to estimate current life expectancy for those Angolans with SCA 
or the long-term benefits of early diagnosis and treatment. We developed several survival 
scenarios using a wide array of data and mortality estimates derived separately from the 
GBD Study 2010 and the Global Health Observatory (GHO) Data Repository life tables. 
The GBD 2010 Study is a rigorous multi-institutional epidemiologic assessment of all 
diseases and injuries with specific analyses for 187 countries.24,25 The GHO Data 
Repository used country-specific data from the WHO to represent best estimates of 
mortality and burden of diseases.26 The 2 data sources have different mortality assumptions, 
and the use of both sources allows for a comprehensive assessment of potential survival 
benefits of NBS based upon available data.
Life tables were generated for 3 groups using both GBD 2010 and GHO data: (1) all 
Angolan children (without consideration of SCA status); (2) Angolan children with SCA; 
and (3) Angolan children with SCA diagnosed by NBS. For the base scenario, we assumed 
that with NBS and associated clinical care: (1) the mortality for infants less than 5 years of 
age with SCA is improved to that of the general population of Angolan children; and (2) 
there is no survival benefit past age 5 years. That scenario is supported by the short-term 
outcomes of the pilot program.11 A second, more conservative scenario assumed that excess 
mortality in infancy is eliminated, that excess mortality relative to other Angolan children 
between ages 1 and 9 years is reduced by 50% and mortality is unchanged past age 9 years.
Estimates of Increased Morbidity in Survivors
Additional disability was assumed to occur in patients with SCA who survived as a result of 
this intervention, the same as for all survivors with SCA. This made our overall estimate of 
HLYs smaller relative to the number of life-years saved. HRQoL scores were approximated 
as 1 minus DW from the GBD Study 2010 for individuals with SCA and moderate 
anemia.23 Reflecting the combined disability associated with repeated vaso-occlusive events 
leading to pain crises, acute chest syndrome, splenic sequestration, and stroke, the estimated 
mean DW increased with age, from 0.109 at age 0-4 years to 0.237 for adults age 40 years 
and over.
Discounting
As per WHO-CHOICE methodology,20 we discounted both costs and health effects in future 
years at 3% per annum for the base case model. Because some argue that health outcomes 
should either not be discounted or discounted at a lower rate than costs, we performed 
sensitivity analyses in which health effects were discounted at a rate of 0% and costs at 6%.
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A total of 550 infants (1.51%) were identified with SCA over the first 23 months of the pilot 
NBS program.11 For the purposes of this analysis, 505 age-eligible (greater than 8 weeks) 
infants were used, the age at which infants were first contacted to enter clinical care. Of 
these 505 infants, 274 (54%) were successfully contacted. Excluding infants who died in the 
neonatal period (n = 11), families who refused care (n = 7), infants with confirmatory tests 
not consistent with the initial diagnosis (n = 10), and families who moved from Luanda (n = 
2), 244 infants ultimately were brought into care. Once infants were enrolled in the clinic, 
continuity of care was 96.8%, with only 8 patients “lost to follow-up” for various reasons.11
The actual number of patients compliant with follow-up (236) was used for all CEA 
calculations. Patients defined as being compliant with follow-up included those who 
presented to the clinic within 6 months of the data analysis and excluded those who actively 
withdrew from care at the clinic for various reasons. Although some of the infants diagnosed 
by NBS but not successfully contacted later presented to care with clinical symptoms, 
treatment costs for these infants were not included in this analysis, as the purpose of CEA is 
to identify which costs and outcomes differ because an intervention is delivered and the 
infants presumably would have been treated for their symptoms in the absence of NBS. 
Figure 1 illustrates estimated survival of Angolan children with and without SCA, with and 
without NBS.
Cost of NBS and Follow-Up Care
The Table provides a detailed summary of the costs of NBS and treatment in this pilot 
program, including both undiscounted and discounted calculations. The total cost to screen 
36 453 infants and to treat 236 infants for 5 years, including medications, training, and 
clinical staff is estimated to be $1 707 654. Discounting costs at 3% results in a discounted 
program cost of $1 610 565. For purposes of the sensitivity analysis, a 6% discounting rate 
was used, resulting in discounted program cost of $1 525 618.
CEA
Using life tables generated from the GBD Study 2010 data, a 3% discount rate, and the 
different mortality assumptions previously discussed, NBS and treatment is projected to 
result in the gain of 452-570 HLYs. The sensitivity analysis, using a 0% discounting rate for 
health effects and 6% discounting of costs, projects that 760-899 HLYs will be gained. The 
corresponding estimated cost per HLY gained is in the range of $1697 to $3565. 
Calculations based on GHO data using the same discounting rates and assumptions result in 
similar projections (gain of 645-1105 HLYs; cost per HLY gained $1380-$2496). Figure 2 
demonstrates the range of expected gains in HLYs according to the various assumptions and 
datasets used.
Discussion
Our analyses demonstrate that the cost per HLY gained for NBS and treatment in Luanda 
($1380-$3565) is lower than the annual per capita gross domestic product (GDP) in Angola 
($5701). The results of this study, therefore, indicate that NBS for SCA is a highly cost-
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effective intervention in the resource-limited setting of Luanda, Angola. As suggested by the 
Commission on Macroeconomics and Health, interventions are considered “highly cost-
effective” if the cost per DALY averted (or HLY gained) is less than per capita GDP, and 
“cost effective” if less than 3 times the per capita GDP.27
Data on the survival of children with SCA, with and without NBS, are lacking in Angola. 
This analysis used several assumptions about mortality and the survival benefits of NBS and 
treatment with an attempt not to overstate the possible survival benefits of NBS and 
treatment. Although there are no data from Africa, reports from the US, United Kingdom, 
and Jamaica demonstrate the survival benefits for children with SCA identified by NBS, 
although it is difficult to extract the specific benefits of NBS, preventive care, and acute 
clinical care.5-8,28,29 Our model indicates that NBS and simple preventive treatments are 
highly cost-effective across all scenarios, regardless of which mortality assumptions or 
datasets were used. Compared with the US, the incremental cost-effectiveness ratios are 
greater for NBS in Angola. This is due to the high prevalance of SCA among newborns, the 
higher early mortality associated with late diagnosis, and the lower cost of healthcare 
personnel in Angola. No reference can be made to CEAs of other health interventions in 
Angola because no other published studies of this type have been identified.
Few studies have documented the cost of providing medical care to children with SCA in 
Africa. The annual cost of care per patient in this cohort in Luanda is approximately I$1000. 
In Kenya, the annual cost of caring for a child with SCA in a rural hospital outpatient clinic 
was reported to be approximately $150.30 Annual labor cost for the Kilifi clinic in Kenya, 
roughly $31 000,30 is much lower than in the Luanda clinic, approximately I$144 000 
(Table), or $95 000 using the market exchange rate (results not reported). The high price 
level in Angola resulting from a petroleum-dominated economy leads to relatively high 
salaries compared with most African countries. It is important not to extrapolate data from 
another setting but to collect locally relevant cost information.
There are several limitations to a study of this nature. First, because our analysis calculated 
HLYs gained instead of DALYs averted, it is likely that our results appear less cost-
effective. DALYs averted is based on a global standard life table for deaths averted, which 
tends to exaggerate the health gain in high mortality settings such as Angola. On the other 
hand, the framework of the Global Burden of Disease methodology is ideal for these types 
of analyses, so additional comparable literature is likely to be forthcoming. Second, our 
study accounts for the development of initial laboratory capacity, the program was fortunate 
enough to expand the care already provided in a pre-existing pediatric sickle cell clinic. This 
may have resulted in systematically underestimated costs and/or overestimated laboratory 
efficiency. For locations where there is no existing sickle cell clinic or trained staff, it will 
be important to incorporate the cost of building such capacity to comprehensively assess the 
costs of developing a NBS and treatment program in these settings. Third, our analysis was 
based on the percentage of contacted families whose babies completed follow-up. 
Unfortunately, given the limited resources of the pilot program and the difficulties faced in 
Luanda, just over one-half of the babies identified by NBS as having SCA were located and 
brought into clinical care. With improved resources and more concentrated efforts to locate 
affected infants, the survival benefits and cost-effectiveness of NBS may be even more 
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pronounced than this analysis suggests. Fourth, although each step of the treatment process 
was performed by Angolan staff, the program was heavily supported by a US academic 
partner. Although the pilot program improved capacity within Angola, the transition of the 
overall program toward a totally Angolan program has been challenging and is still in 
progress. Cost estimates for Angolan personnel to replace crucial foreign staff also are 
somewhat speculative and may be low. Finally, our assumption could be challenged that the 
IT infrastructure based in the US was not required for the operation of the program and was 
not critical to the operations of the screening and treatment program. This assumption would 
underestimate cost.
In addition, the frequency and cost of health care utilization for acute complications of SCA 
were not included in this analysis, as per the WHO-CHOICE methodology. However, 
children with SCA who survive the newborn period are likely to have high utilization of the 
healthcare system, which will result in increased healthcare costs. Data regarding the 
frequency or cost of acute care utilization were not available for this patient population, as 
acute care was received primarily at local health centers or in the emergency departments, 
which both have separate record keeping systems from the sickle cell clinic. It will be 
critical to evaluate the frequency and cost of emergency and inpatient care to further 
describe the overall cost and cost-effectiveness of comprehensive sickle cell care throughout 
childhood.
Extrapolation of these Angolan data to other African countries should be done with caution, 
as each country has a unique economy and healthcare system with variable per capita health 
expenditure, local healthcare costs, and variable mortality rates. It will be critical to obtain 
local cost data and to show that the health benefits of NBS and treatment are reproducible in 
different settings.
Overall, mortality rates in sub-Saharan African infants under 5 years of age have fallen over 
the past 2 decades, primarily because of targeted efforts against vaccine-preventable 
diseases, HIV/AIDS, diarrhea, and malaria.31-33 SCA is a tremendously under-recognized 
public health challenge that has been estimated to contribute up to 5% of under 5-year 
mortality on the African continent. It is likely that the survival of infants with SCA will 
improve through universal public health efforts such as pneumococcal immunization, but the 
significant contribution of SCA to childhood mortality remains largely unaddressed because 
of lack of recognition of the scale of the problem. Based on this analysis, NBS and 
preventive care for SCA in the resource-limited setting of Luanda is both feasible and highly 
cost-effective. Universal NBS and access to early preventive care should be considered in 
the development of national healthcare strategies within sub-Saharan Africa.
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DW Disability weight
GBD Global Burden of Diseases, Injuries, and Risk Factors
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GHO Global Health Observatory
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I$ International dollars
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Survival of infants with SCA in Angola with and without the availability of NBS and 
treatment are not known.
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Two datasets were used for the purposes of estimating mortality and HLYs gained by NBS. 
Given lack of precise data regarding follow-up or mortality, 4 scenarios were used to 
estimate the cost per HLY-gained by NBS and treatment. NBS and treatment appears to be 
highly cost-effective regardless of which assumptions or datasets used, with an estimated 
cost per HLY gained of $1380-$3565.
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Table
Summary of NBS and treatment costs
Cost of screening and testing 36 453 infants over 23 months
Cost with 3% discounting Cost with 6% discounting
Total cost, I$ (no discounting) Per infant Total Per infant Total
Collection supplies 141 208 3.82 139 241 3.77 137 385
Maternity hospital labor costs 129 594 3.50 127 789 3.46 126 086
Specimen transport 22 896 0.62 22 577 0.61 22 276
Laboratory personnel 171 717 4.65 169 325 4.58 167 069
Laboratory reagents/supplies 88 366 2.39 87 135 2.36 85 974
Equipment (annualized cost) 13 913 0.38 13 720 0.37 13 537
Total screening costs 567 694 15.36 559 787 15.15 552 327
Treatment costs for 236 children with SCA through age 5 years
Total cost, I$ (no discounting) Cost with 3% discounting Cost with 6% discounting
Clinic personnel 719 941 663 618 614 681
Medications, laboratories, and
 treatments
83 901 77 337 71 634
Physical space, information technology,
 and overhead
336 118 309 823 286 976
Total treatment costs 1 139 960 1 050 778 973 291
Total cost of NBS and treatment (no discounting): $1 707 654
Total cost of NBS and treatment (3%): $1 610 565
Total cost of NBS and treatment (6%): $1 525 618
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